David Cole to Deoxycytidine
This is a "connection" page, showing publications David Cole has written about Deoxycytidine.
Connection Strength
0.152
-
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.
Score: 0.101
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
Score: 0.027
-
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer. J Surg Res. 2012 Aug; 176(2):359-66.
Score: 0.023